Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERMAID: melflufen and dexamethasone re-induction with continued daratumumab in daratumumab-refractory multiple myeloma
2020-004349-35Phase 2Terminated
- Sponsor
- Sygehus Lillebælt
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan flufenamide, daratumumab and dexamethasone in multiple myeloma (MM), sponsored by Sygehus Lillebælt. Primary endpoint: Primary end-point. Started Feb 2021; status: terminated.
02
Drugs
melphalan flufenamidedaratumumabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-004349-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004349-35.